{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T21:34:03Z","timestamp":1757626443979,"version":"3.44.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["MSc","a Ph.D of the Fund for Scientific Research"],"award-info":[{"award-number":["MSc","a Ph.D of the Fund for Scientific Research"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Patients with neuromuscular diseases (NMD) have undergone considerable technological progress in terms of diagnosis and treatment over the past few years. Specifically, next-generation sequencing (NGS) has significantly expanded genetic diagnosis. Despite this, some patients remain undiagnosed and therefore without access to specific treatments. Analyses of epidemiology and diagnostic approaches in reference centers are required to determine effective strategies to improve diagnostic rates.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We studied the proportion of each NMD and associated investigations in the patient population of the Neuromuscular Reference Center (NMRC) of Liege, Belgium, in 2023. The investigation tools used included laboratory testing, muscle biopsy, muscle imaging, single-gene sequencing, targeted NGS panels, and whole-exome sequencing (WES).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of the 1084 patients who were regularly followed up, more than one-third had neuropathies (36.6%) that were divided equally between genetic and acquired causes. The second most common disorder was muscular dystrophies, which represented more than a quarter (27.5%). Third, 11.2% of the patients had motor neuron diseases. The other NMD (i.e., myopathies, ataxias, spastic paraplegias, and channelopathies) ranged from 2.1% to 6.\u00a0%. A total of 13.7% of the patients had unconfirmed diagnoses, 31.5% had confirmed acquired disorders, and 54.9% had genetically confirmed disorders. Among the genetic diagnoses, 32.7% were obtained by NGS. The remaining 67.3% were determined using other genetic testing methods [i.e., array comparative genomic hybridization (aCGH), multiplex ligation-dependent probe amplification (MLPA), polymerase chain reaction (PCR), southern blotting (SB)].<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>More than two-thirds of patients received a definitive diagnosis without the use of next-generation sequencing. Although innovative technologies such as whole genome sequencing and long-read sequencing are expected to eventually replace NGS panels and traditional methods (e.g., MLPA, PCR, aCGH), their current cost and the complexity of variant interpretation limit their widespread use in routine clinical practice. As a result, these older techniques remain relevant and valuable in current diagnostic workflow.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03963-2","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T18:17:49Z","timestamp":1756491469000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Epidemiological report and diagnostic approach used in the neuromuscular population of Liege, Belgium"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9569-9229","authenticated-orcid":false,"given":"Charlotte","family":"Mouraux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Dangouloff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaux","family":"Poleur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurane","family":"Mackels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Vanden Brande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurore","family":"Daron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Servais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Maertens de Noordhout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Delstanche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"3963_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3109\/10408363.2012.658906","volume":"49","author":"NG Laing","year":"2012","unstructured":"Laing NG. Genetics of neuromuscular disorders. Crit Rev Clin Lab Sci. 2012;49:33\u201348.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"3963_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0261983","author":"IM Carey","year":"2021","unstructured":"Carey IM, Banchoff E, Nirmalananthan N, Harris T, DeWilde S, Chaudhry UAR, et al. Prevalence and incidence of neuromuscular conditions in the UK between 2000 and 2019: a retrospective study using primary care data. PLoS ONE. 2021. https:\/\/doi.org\/10.1371\/journal.pone.0261983.","journal-title":"PLoS ONE"},{"key":"3963_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1948","volume":"11","author":"KI M\u00fcller","year":"2021","unstructured":"M\u00fcller KI, Ghelue MV, Lund I, Jonsrud C, Arntzen KA. The prevalence of hereditary neuromuscular disorders in Northern Norway. Brain Behav. 2021;11: e01948.","journal-title":"Brain Behav"},{"key":"3963_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3233\/JND-140032","volume":"1","author":"M Lek","year":"2014","unstructured":"Lek M, MacArthur D. The challenge of next generation sequencing in the context of neuromuscular diseases. J Neuromuscul Dis. 2014;1:135\u201349.","journal-title":"J Neuromuscul Dis"},{"key":"3963_CR5","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.tig.2022.07.001","volume":"38","author":"KE Koczwara","year":"2022","unstructured":"Koczwara KE, Lake NJ, DeSimone AM, Lek M. Neuromuscular disorders: finding the missing genetic diagnoses. Trends Genet. 2022;38:956\u201371.","journal-title":"Trends Genet"},{"key":"3963_CR6","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.nmd.2023.12.007","volume":"34","author":"L Benarroch","year":"2024","unstructured":"Benarroch L, Bonne G, Rivier F, Hamroun D. The 2024 version of the gene table of neuromuscular disorders (nuclear genome). Neuromuscul Disord. 2024;34:126\u201370.","journal-title":"Neuromuscul Disord"},{"key":"3963_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-024-01699-4","author":"B Est\u00e9vez-Arias","year":"2024","unstructured":"Est\u00e9vez-Arias B, Matalonga L, Yubero D, Polavarapu K, Codina A, Ortez C, et al. Phenotype-driven genomics enhance diagnosis in children with unresolved neuromuscular diseases. Eur J Hum Genet. 2024. https:\/\/doi.org\/10.1038\/s41431-024-01699-4.","journal-title":"Eur J Hum Genet"},{"key":"3963_CR8","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.1016\/j.otsr.2017.04.019","volume":"104","author":"P Mary","year":"2018","unstructured":"Mary P, Servais L, Vialle R. Neuromuscular diseases: Diagnosis and management. Orthop Traumatol Surg Res. 2018;104:S89-95.","journal-title":"Orthop Traumatol Surg Res"},{"key":"3963_CR9","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/jns.12455","volume":"26","author":"PYK Van den Bergh","year":"2021","unstructured":"Van den Bergh PYK, van Doorn PA, Hadden RDM, Avau B, Vankrunkelsven P, Allen JA, et al. European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force\u2014Second revision. J Peripher Nerv Syst. 2021;26:242\u201368.","journal-title":"J Peripher Nerv Syst"},{"key":"3963_CR10","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/genes14071377","volume":"14","author":"K Aragon-Gawinska","year":"2023","unstructured":"Aragon-Gawinska K, Mouraux C, Dangouloff T, Servais L. Spinal muscular atrophy treatment in patients identified by newborn screening-a systematic review. Genes (Basel). 2023;14:1377.","journal-title":"Genes (Basel)."},{"key":"3963_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/mus.27337","volume":"64","author":"S Nicolau","year":"2021","unstructured":"Nicolau S, Milone M, Liewluck T. Guidelines for genetic testing of muscle and neuromuscular junction disorders. Muscle Nerve. 2021;64:255\u201369.","journal-title":"Muscle Nerve"},{"key":"3963_CR12","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1002\/ajmg.a.63356","volume":"191","author":"A Rosenberg","year":"2023","unstructured":"Rosenberg A, Tian C, He H, Ulm E, Collins Ruff K, Nagaraj CB. An evaluation of clinical presentation and genetic testing approaches for patients with neuromuscular disorders. Am J Med Genet A. 2023;191:2679\u201392.","journal-title":"Am J Med Genet A"},{"key":"3963_CR13","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000341","volume":"5","author":"S Nicolau","year":"2019","unstructured":"Nicolau S, Liewluck T, Tracy JA, Laughlin RS, Milone M. Congenital myopathies in the adult neuromuscular clinic: Diagnostic challenges and pitfalls. Neurol Genet. 2019;5: e341.","journal-title":"Neurol Genet."},{"issue":"3","key":"3963_CR14","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.nrleng.2024.02.008","volume":"40","author":"R Sivera Mascar\u00f3","year":"2024","unstructured":"Sivera Mascar\u00f3 R, Garc\u00eda Sobrino T, Horga Hern\u00e1ndez A, Pelayo Negro AL, Alonso Jim\u00e9nez A, Antelo Pose A, et al. Clinical practice guidelines for the diagnosis and management of Charcot-Marie-Tooth disease. Neurolog\u00eda (English Edition). 2024;40(3):290\u2013305.","journal-title":"Neurolog\u00eda (English Edition)."},{"key":"3963_CR15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3233\/JND-170231","volume":"4","author":"K Vill","year":"2017","unstructured":"Vill K, Blaschek A, Gl\u00e4ser D, Kuhn M, Haack T, Alhaddad B, et al. Early-onset myopathies: clinical findings, prevalence of subgroups and diagnostic approach in a single neuromuscular referral center in Germany. J Neuromuscul Dis. 2017;4:315\u201325.","journal-title":"J Neuromuscul Dis"},{"key":"3963_CR16","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.nmd.2021.11.004","volume":"31","author":"E Cohen","year":"2021","unstructured":"Cohen E, Bonne G, Rivier F, Hamroun D. The 2022 version of the gene table of neuromuscular disorders (nuclear genome). Neuromuscul Disord. 2021;31:1313\u201357.","journal-title":"Neuromuscul Disord"},{"key":"3963_CR17","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/mds.28982","volume":"37","author":"LM Lange","year":"2022","unstructured":"Lange LM, Gonzalez-Latapi P, Rajalingam R, Tijssen MAJ, Ebrahimi-Fakhari D, Gabbert C, et al. Nomenclature of genetic movement disorders: recommendations of the International Parkinson and Movement Disorder Society Task Force - an update. Mov Disord. 2022;37:905\u201335.","journal-title":"Mov Disord"},{"key":"3963_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-99496-2","author":"F Boemer","year":"2021","unstructured":"Boemer F, Caberg JH, Beckers P, Dideberg V, di Fiore S, Bours V, et al. Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium. Sci Rep. 2021. https:\/\/doi.org\/10.1038\/s41598-021-99496-2.","journal-title":"Sci Rep"},{"key":"3963_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3233\/JND-140045","volume":"2","author":"JCW Deenen","year":"2015","unstructured":"Deenen JCW, Horlings CGC, Verschuuren JJGM, Verbeek ALM, Van Engelen BGM. The epidemiology of neuromuscular disorders: a comprehensive overview of the literature. J Neuromuscul Dis. 2015;2:73\u201385.","journal-title":"J Neuromuscul Dis"},{"key":"3963_CR20","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1001\/archneur.60.12.1755","volume":"60","author":"P Magda","year":"2003","unstructured":"Magda P, Latov N, Brannagan TH, Weimer LH, Chin RL, Sander HW. Comparison of electrodiagnostic abnormalities and criteria in a cohort of patients with chronic inflammatory demyelinating polyneuropathy. Arch Neurol. 2003;60:1755\u20139.","journal-title":"Arch Neurol"},{"key":"3963_CR21","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1093\/brain\/awp236","volume":"132","author":"FLM Norwood","year":"2009","unstructured":"Norwood FLM, Harling C, Chinnery PF, Eagle M, Bushby K, Straub V. Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain. 2009;132:3175\u201386.","journal-title":"Brain"},{"key":"3963_CR22","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/mus.24969","volume":"53","author":"K Farhad","year":"2016","unstructured":"Farhad K, Traub R, Ruzhansky KM, Brannagan TH. Causes of neuropathy in patients referred as \u201cidiopathic neuropathy.\u201d Muscle Nerve. 2016;53:856\u201361.","journal-title":"Muscle Nerve"},{"key":"3963_CR23","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1093\/brain\/awab072","volume":"144","author":"R Curr\u00f2","year":"2021","unstructured":"Curr\u00f2 R, Salvalaggio A, Tozza S, Gemelli C, Dominik N, Galassi Deforie V, et al. RFC1 expansions are a common cause of idiopathic sensory neuropathy. Brain. 2021;144:1542\u201350.","journal-title":"Brain"},{"key":"3963_CR24","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/s41582-019-0254-5","volume":"15","author":"M Pipis","year":"2019","unstructured":"Pipis M, Rossor AM, Laura M, Reilly MM. Next-generation sequencing in Charcot-Marie-Tooth disease: opportunities and challenges. Nat Rev Neurol. 2019;15:644\u201356.","journal-title":"Nat Rev Neurol"},{"key":"3963_CR25","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/mus.21973","volume":"43","author":"B Gess","year":"2011","unstructured":"Gess B, Jeibmann A, Schirmacher A, Kleffner I, Schilling M, Young P. Report of a novel mutation in the PMP22 gene causing an axonal neuropathy. Muscle Nerve. 2011;43:605\u20139.","journal-title":"Muscle Nerve"},{"key":"3963_CR26","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1212\/WNL.0000000000003772","volume":"88","author":"B Bansagi","year":"2017","unstructured":"Bansagi B, Griffin H, Whittaker RG, Antoniadi T, Evangelista T, Miller J, et al. Genetic heterogeneity of motor neuropathies. Neurology. 2017;88:1226\u201334.","journal-title":"Neurology"},{"key":"3963_CR27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000367634","volume":"43","author":"S Lefter","year":"2014","unstructured":"Lefter S, Hardiman O, Ryan AM. Methodology and design of a national epidemiological study on adult neuromuscular disease. Neuroepidemiology. 2014;43:123\u201330.","journal-title":"Neuroepidemiology"},{"key":"3963_CR28","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3233\/JND-210652","volume":"9","author":"A Megarbane","year":"2022","unstructured":"Megarbane A, Bizzari S, Deepthi A, Sabbagh S, Mansour H, Chouery E, et al. A 20-year clinical and genetic neuromuscular cohort analysis in Lebanon: an international effort. J Neuromuscul Dis. 2022;9:193\u2013210.","journal-title":"J Neuromuscul Dis"},{"key":"3963_CR29","doi-asserted-by":"publisher","first-page":"125","DOI":"10.33192\/Smj.2020.17","volume":"72","author":"A Thongsing","year":"2020","unstructured":"Thongsing A, Likasitwattanakula S, Netsuwan T, Sanmaneechai O. Pediatric neuromuscular diseases prevalence in Siriraj Hospital, Thailand\u2019s largest tertiary referral hospital. Siriraj Med J. 2020;72:125\u201331.","journal-title":"Siriraj Med J"},{"key":"3963_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01353-4","author":"P Vanherpe","year":"2020","unstructured":"Vanherpe P, Fieuws S, D\u2019Hondt A, Bleyenheuft C, Demaerel P, De Bleecker J, et al. Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures. Orphanet J Rare Dis. 2020. https:\/\/doi.org\/10.1186\/s13023-020-01353-4.","journal-title":"Orphanet J Rare Dis"},{"key":"3963_CR31","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(22)00125-9","volume":"21","author":"T Markati","year":"2022","unstructured":"Markati T, Oskoui M, Farrar MA, Duong T, Goemans N, Servais L. Emerging therapies for Duchenne muscular dystrophy. Lancet Neurol. 2022;21:814\u201329.","journal-title":"Lancet Neurol"},{"key":"3963_CR32","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/s41431-020-0643-7","volume":"28","author":"C Fratter","year":"2020","unstructured":"Fratter C, Dalgleish R, Allen SK, Santos R, Abbs S, Tuffery-Giraud S, et al. EMQN best practice guidelines for genetic testing in dystrophinopathies. Eur J Human Genet. 2020;28:1141\u201359.","journal-title":"Eur J Human Genet."},{"key":"3963_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/cge.14533","volume":"106","author":"E Giardina","year":"2024","unstructured":"Giardina E, Cama\u00f1o P, Burton-Jones S, Ravenscroft G, Henning F, Magdinier F, et al. Best practice guidelines on genetic diagnostics of facioscapulohumeral muscular dystrophy: update of the 2012 guidelines. Clin Genet. 2024;106:13\u201326.","journal-title":"Clin Genet"},{"issue":"270","key":"3963_CR34","first-page":"293","volume":"1995","author":"S Labeit","year":"1979","unstructured":"Labeit S, Kolmerer B. Titins: giant proteins in charge of muscle ultrastructure and elasticity. Science. 1979;1995(270):293\u20136.","journal-title":"Science"},{"key":"3963_CR35","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/0092-8674(88)90383-2","volume":"53","author":"M Koenig","year":"1988","unstructured":"Koenig M, Monaco AP, Kunkel LM. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell. 1988;53:219\u201328.","journal-title":"Cell"},{"issue":"5","key":"3963_CR36","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2017.4899","volume":"75","author":"M Savarese","year":"2018","unstructured":"Savarese M, Maggi L, Vihola A, Jonson PH, Tasca G, Ruggiero L, et al. Interpreting genetic variants in Titin in patients with muscle disorders. JAMA Neurol. 2018;75(5):557\u201365.","journal-title":"JAMA Neurol"},{"key":"3963_CR37","first-page":"158","volume":"40","author":"SN Bardakov","year":"2021","unstructured":"Bardakov SN, Tsargush VA, Carlier PG, Nikitin SS, Kurbatov SA, Titova AA, et al. Magnetic resonance imaging pattern variability in dysferlinopathy. Acta Myol. 2021;40:158\u201371.","journal-title":"Acta Myol"},{"key":"3963_CR38","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/ajmg.a.61126","volume":"179","author":"N Al-Dewik","year":"2019","unstructured":"Al-Dewik N, Mohd H, Al-Mureikhi M, Ali R, Al-Mesaifri F, Mahmoud L, et al. Clinical exome sequencing in 509 Middle Eastern families with suspected Mendelian diseases: the Qatari experience. Am J Med Genet A. 2019;179:927\u201335.","journal-title":"Am J Med Genet A"},{"key":"3963_CR39","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41431-022-01249-w","volume":"31","author":"E Mavraki","year":"2023","unstructured":"Mavraki E, Labrum R, Sergeant K, Alston CL, Woodward C, Smith C, et al. Genetic testing for mitochondrial disease: the United Kingdom best practice guidelines. Eur J Hum Genet. 2023;31:148\u201363.","journal-title":"Eur J Hum Genet"},{"key":"3963_CR40","doi-asserted-by":"publisher","first-page":"284","DOI":"10.21037\/atm.2019.07.24","volume":"7","author":"A Toscano","year":"2019","unstructured":"Toscano A, Rodolico C, Musumeci O. Multisystem late onset Pompe disease (LOPD): an update on clinical aspects. Ann Transl Med. 2019;7:284\u2013284.","journal-title":"Ann Transl Med"},{"key":"3963_CR41","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000685","volume":"8","author":"B Lace","year":"2022","unstructured":"Lace B, Micule I, Kenina V, Setlere S, Strautmanis J, Kazaine I, et al. Overview of neuromuscular disorder molecular diagnostic experience for the population of Latvia. Neurol Genet. 2022;8: e685.","journal-title":"Neurol Genet."},{"key":"3963_CR42","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1001\/archneur.1995.00540290108025","volume":"52","author":"K Zerres","year":"1995","unstructured":"Zerres K, Sch\u00f6neborn SR. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol. 1995;52:518\u201323.","journal-title":"Arch Neurol"},{"key":"3963_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.107986","author":"A Chi\u00f2","year":"2020","unstructured":"Chi\u00f2 A, Mazzini L, Mora G. Disease-modifying therapies in amyotrophic lateral sclerosis. Neuropharmacology. 2020. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.107986.","journal-title":"Neuropharmacology"},{"key":"3963_CR44","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.nmd.2019.02.003","volume":"29","author":"F Boemer","year":"2019","unstructured":"Boemer F, Caberg JH, Dideberg V, Dardenne D, Bours V, Hiligsmann M, et al. Newborn screening for SMA in Southern Belgium. Neuromuscul Disord. 2019;29:343\u20139.","journal-title":"Neuromuscul Disord"},{"key":"3963_CR45","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1136\/jmedgenet-2021-107776","volume":"59","author":"LM Cairns","year":"2022","unstructured":"Cairns LM, Rankin J, Hamad A, Cooper N, Merrifield K, Jain V, et al. Genetic testing in motor neuron disease and frontotemporal dementia: a 5-year multicentre evaluation. J Med Genet. 2022;59:544\u20138.","journal-title":"J Med Genet"},{"key":"3963_CR46","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1080\/21678421.2022.2150556","volume":"24","author":"HM De Oliveira","year":"2023","unstructured":"De Oliveira HM, Soma A, Baker MR, Turner MR, Talbot K, Williams TL. A survey of current practice in genetic testing in amyotrophic lateral sclerosis in the UK and republic of Ireland: implications for future planning. Amyotroph Lateral Scler Frontotemporal Degener. 2023;24:405\u201313.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"3963_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1170996","volume":"17","author":"H Wang","year":"2023","unstructured":"Wang H, Guan LP, Deng M. Recent progress of the genetics of amyotrophic lateral sclerosis and challenges of gene therapy. Front Neurosci. 2023;17: 1170996.","journal-title":"Front Neurosci"},{"key":"3963_CR48","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1093\/bioinformatics\/bts526","volume":"28","author":"V Plagnol","year":"2012","unstructured":"Plagnol V, Curtis J, Epstein M, Mok KY, Stebbings E, Grigoriadou S, et al. A robust model for read count data in exome sequencing experiments and implications for copy number variant calling. Bioinformatics. 2012;28:2747\u201354.","journal-title":"Bioinformatics"},{"key":"3963_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04243-y","author":"SU Greer","year":"2023","unstructured":"Greer SU, Botello J, Hongo D, Levy B, Shah P, Rabinowitz M, et al. Implementation of nanopore sequencing as a pragmatic workflow for copy number variant confirmation in the clinic. J Transl Med. 2023. https:\/\/doi.org\/10.1186\/s12967-023-04243-y.","journal-title":"J Transl Med"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03963-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03963-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03963-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T22:37:29Z","timestamp":1757457449000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03963-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3963"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03963-2","relation":{},"ISSN":["1750-1172"],"issn-type":[{"type":"electronic","value":"1750-1172"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"12 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project was approved by the Ethics Committee of the Citadelle Hospital of Li\u00e8ge on Oct 19, 2023, with the reference number \u201cJL\/rc\/2093\u201d. Written informed consent was not necessary for this cross-sectional noninterventional study. We confirm that we have read the Journal\u2019s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"S.D. reported disclosures as she was a consultant for Alexion, Alnylam, Argenx, Biogen, Roche, UCB, Janssen Pharmaceuticals and Amikus. T.D. has given lectures sponsored by Biogen, Novartis, and Roche. LS has given vonsultancy\/part of the board for Biogen, Novartis, Roche, Scholar Rock, NMD bipharma, BioHaven, Biomarin, Dyne, Wave, Avidity, Entrada, Pfizer, RegenexBio, Italfarmaco and Santhera.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"464"}}